Agenus Inc (AGEN)vsAlnylam Pharmaceuticals Inc (ALNY)
AGEN
Agenus Inc
$3.56
0.00%
HEALTHCARE · Cap: $142.46M
ALNY
Alnylam Pharmaceuticals Inc
$328.70
+6.70%
HEALTHCARE · Cap: $40.85B
Smart Verdict
WallStSmart Research — data-driven comparison
Alnylam Pharmaceuticals Inc generates 3152% more annual revenue ($3.71B vs $114.20M). ALNY leads profitability with a 8.5% profit margin vs 0.1%. ALNY earns a higher WallStSmart Score of 49/100 (D+).
AGEN
Hold48
out of 100
Grade: D+
ALNY
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for AGEN.
Margin of Safety
-1925.6%
Fair Value
$15.91
Current Price
$328.70
$312.79 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Strong operational efficiency at 42.1%
Conservative balance sheet, low leverage
Revenue surging 27.5% year-over-year
Every $100 of equity generates 73 in profit
Revenue surging 84.9% year-over-year
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.1% margin — thin
ROE of -12.8% — below average capital efficiency
0.0% earnings growth
Premium valuation, high expectations priced in
Trading at 55.2x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AGEN
The strongest argument for AGEN centers on Operating Margin, Debt/Equity, Revenue Growth. Revenue growth of 27.5% demonstrates continued momentum. PEG of 1.44 suggests the stock is reasonably priced for its growth.
Bull Case : ALNY
The strongest argument for ALNY centers on Return on Equity, Revenue Growth. Revenue growth of 84.9% demonstrates continued momentum.
Bear Case : AGEN
The primary concerns for AGEN are EPS Growth, Market Cap, Profit Margin. Thin 0.1% margins leave little buffer for downturns.
Bear Case : ALNY
The primary concerns for ALNY are EPS Growth, P/E Ratio, Price/Book. A P/E of 131.7x leaves little room for execution misses.
Key Dynamics to Monitor
AGEN profiles as a growth stock while ALNY is a hypergrowth play — different risk/reward profiles.
AGEN carries more volatility with a beta of 1.67 — expect wider price swings.
ALNY is growing revenue faster at 84.9% — sustainability is the question.
ALNY generates stronger free cash flow (140M), providing more financial flexibility.
Bottom Line
ALNY scores higher overall (49/100 vs 48/100) and 84.9% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Agenus Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company is headquartered in Lexington, Massachusetts.
Visit Website →Alnylam Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing and commercializing RNA interference (RNAi) therapies. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?